FR2790473B1 - Nouveaux composes et medicaments les contenant - Google Patents

Nouveaux composes et medicaments les contenant

Info

Publication number
FR2790473B1
FR2790473B1 FR0002170A FR0002170A FR2790473B1 FR 2790473 B1 FR2790473 B1 FR 2790473B1 FR 0002170 A FR0002170 A FR 0002170A FR 0002170 A FR0002170 A FR 0002170A FR 2790473 B1 FR2790473 B1 FR 2790473B1
Authority
FR
France
Prior art keywords
new compounds
medicaments containing
medicaments
compounds
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0002170A
Other languages
English (en)
Other versions
FR2790473A1 (fr
Inventor
Michael Bos
Quirico Branca
Guido Galley
Thierry Godel
Torsten Hoffmann
Walter Hunkeler
Patrick Schnider
Heinz Stadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of FR2790473A1 publication Critical patent/FR2790473A1/fr
Application granted granted Critical
Publication of FR2790473B1 publication Critical patent/FR2790473B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR0002170A 1999-02-24 2000-02-22 Nouveaux composes et medicaments les contenant Expired - Fee Related FR2790473B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99103504 1999-02-24
EP99123689 1999-11-29

Publications (2)

Publication Number Publication Date
FR2790473A1 FR2790473A1 (fr) 2000-09-08
FR2790473B1 true FR2790473B1 (fr) 2004-04-02

Family

ID=26152908

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0002170A Expired - Fee Related FR2790473B1 (fr) 1999-02-24 2000-02-22 Nouveaux composes et medicaments les contenant
FR15C0049C Active FR15C0049I2 (fr) 1999-02-24 2015-07-08 Dérivés de 4-phenylpyridine et leur utilisation comme antagonistes du recepteur NK-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR15C0049C Active FR15C0049I2 (fr) 1999-02-24 2015-07-08 Dérivés de 4-phenylpyridine et leur utilisation comme antagonistes du recepteur NK-1

Country Status (55)

Country Link
US (2) US6297375B1 (fr)
EP (2) EP1035115B1 (fr)
JP (1) JP3399900B2 (fr)
KR (1) KR100384904B1 (fr)
CN (1) CN1142144C (fr)
AR (2) AR029614A1 (fr)
AT (2) ATE496032T1 (fr)
AU (1) AU767048B2 (fr)
BE (1) BE2015C057I2 (fr)
BG (1) BG64554B1 (fr)
BR (1) BRPI0000908B8 (fr)
CA (1) CA2299139C (fr)
CY (3) CY1111317T1 (fr)
CZ (1) CZ300596B6 (fr)
DE (3) DE60014216T2 (fr)
DK (2) DK1394150T3 (fr)
EA (1) EA003673B1 (fr)
EG (1) EG23817A (fr)
ES (3) ES2359235T3 (fr)
FR (2) FR2790473B1 (fr)
GB (1) GB2347422A (fr)
GE (1) GEP20022676B (fr)
GT (1) GT200000017A (fr)
HK (1) HK1031223A1 (fr)
HR (2) HRP20000097B1 (fr)
HU (1) HU227629B1 (fr)
IL (1) IL134654A (fr)
IS (1) IS2116B (fr)
IT (1) IT1320763B1 (fr)
JO (1) JO2294B1 (fr)
LT (1) LTC1035115I2 (fr)
LU (1) LU92745I2 (fr)
MA (1) MA26722A1 (fr)
ME (1) ME00593B (fr)
MY (2) MY123648A (fr)
NL (1) NL300758I1 (fr)
NO (1) NO315554B1 (fr)
NZ (1) NZ502948A (fr)
OA (1) OA11680A (fr)
PA (1) PA8491101A1 (fr)
PE (1) PE20001467A1 (fr)
PL (1) PL217311B1 (fr)
PT (2) PT1035115E (fr)
RS (3) RS53869B1 (fr)
SE (1) SE1035115T5 (fr)
SG (1) SG91856A1 (fr)
SI (1) SI1035115T1 (fr)
SK (2) SK287912B6 (fr)
SV (1) SV2002000024A (fr)
TN (1) TNSN00032A1 (fr)
TR (1) TR200000520A2 (fr)
TW (1) TWI288746B (fr)
UA (1) UA71547C2 (fr)
UY (1) UY32314A (fr)
ZA (1) ZA200000894B (fr)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058640A2 (fr) * 1998-05-11 1999-11-18 Philadelphia Health And Education Corporation Ct-1, un oncogene humain
WO2000050398A2 (fr) * 1999-02-24 2000-08-31 F. Hoffmann-La Roche Ag Derives de pyridinyl et de phenyle
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
DE60006340T2 (de) * 1999-11-29 2004-09-09 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramid
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
JP3938651B2 (ja) * 2000-04-13 2007-06-27 セントラル硝子株式会社 光学活性α−メチル−ビス−３、５−（トリフルオロメチル）ベンジルアミンの製造方法
WO2002006236A1 (fr) * 2000-07-14 2002-01-24 F. Hoffmann-La Roche Ag N-oxydes en tant que promedicaments de derives de 4-phenyl-pyridine, antagonistes du recepteur nk1
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
PT1349541E (pt) 2000-12-14 2007-01-31 Hoffmann La Roche Matriz lipídica auto-emulsionante (selm)
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
WO2002076973A1 (fr) * 2001-03-27 2002-10-03 Eisai Co., Ltd. Derive d'amine cyclique a substitution n-aryle et medicament contenant ledit derive en tant que principe actif
CA2444395C (fr) * 2001-04-23 2010-12-21 F. Hoffmann-La Roche Ag Utilisation d'antagonistes de recepteur de nk-1 contre l'hyperplasie benigne de la prostate
CA2449987C (fr) * 2001-06-07 2015-11-03 Christine N. Sang Traitement de la douleur neuropathique centrale
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
BRPI0212299B1 (pt) * 2001-09-10 2016-03-15 Hoffmann La Roche veículo tixotrópico oleoso, seu processo de preparação, massa de enchimento, e dose unitária farmacêutica
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
JP2006508061A (ja) 2002-09-20 2006-03-09 ファイザー・プロダクツ・インク エストロゲン受容体に対するアミドおよびスルホンアミドリガンド
EP1567497B1 (fr) 2002-12-06 2009-09-23 Purdue Research Foundation Pyridines destinees au traitement de tissus nerveux mammaliens leses
US8729107B2 (en) * 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
NZ541243A (en) 2003-01-31 2008-04-30 Hoffmann La Roche New crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
JP4490421B2 (ja) * 2003-07-03 2010-06-23 エフ．ホフマン−ラ ロシュ アーゲー 統合失調症を処置するデュアルｎｋ１／ｎｋ３アンタゴニスト
TWI280239B (en) * 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
US7335658B2 (en) 2003-07-30 2008-02-26 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
MX2007000028A (es) * 2004-07-06 2007-07-20 Xenon Pharmaceuticals Inc Derivados de nicotinamida y su uso como agentes terapeuticos.
JP4580426B2 (ja) * 2004-07-06 2010-11-10 エフ．ホフマン−ラ ロシュ アーゲー Ｎｋ−１受容体拮抗薬の合成において中間体として使用されるカルボキサミド誘導体の製造方法
KR100881240B1 (ko) * 2004-07-06 2009-02-05 에프. 호프만-라 로슈 아게 Ｎｋ-1 수용체 길항제의 합성에 있어서 중간체로서사용되는 카르복스아미드 피리딘 유도체의 제조 방법
WO2006013205A1 (fr) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Antagonistes des récepteurs de la neurokinine-1 pour le traitement des états sensibles à une élévation de la testostérone
US20060030556A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
CA2580787A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et utilisation de ceux-ci comme agents therapeutiques
AR051092A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
CN101083992A (zh) 2004-09-20 2007-12-05 泽农医药公司 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP2269610A3 (fr) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase
US7569725B2 (en) * 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3
WO2006060174A1 (fr) * 2004-11-15 2006-06-08 Honeywell International Inc. Mousses polymeres a base d'isocyanate avec des materiaux a nano-echelle
JP4767973B2 (ja) 2005-02-22 2011-09-07 エフ．ホフマン−ラ ロシュ アーゲー Ｎｋ１アンタゴニスト
US7671065B2 (en) * 2005-02-24 2010-03-02 Janssen Pharmaceutica N.V. Pyridine derivatives as potassium ion channel openers
EP1855655A2 (fr) 2005-02-25 2007-11-21 F. Hoffmann-Roche AG Comprimés présentant une dispersibilité de substance médicamenteuse améliorée
RU2404969C2 (ru) * 2005-03-23 2010-11-27 Ф. Хоффманн-Ля Рош Аг Метаболиты антагонистов nk-1 против рвоты
CA2618646A1 (fr) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine
EP1912983B1 (fr) * 2005-08-11 2011-06-08 Vertex Pharmaceuticals, Inc. Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique
AR058805A1 (es) 2005-09-09 2008-02-27 Smithkline Beecham Corp Derivados biciclicos de piridina utiles como agentes antipsicoticos
CN101267808A (zh) * 2005-09-23 2008-09-17 弗·哈夫曼-拉罗切有限公司 新型制剂
SI2395002T1 (sl) * 2005-11-08 2014-10-30 Vertex Pharmaceuticals Incorporated Farmacevtski sestavek, vsebujoč heterociklični modulator prenašalcev z ATP-vezavno kaseto
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7872022B2 (en) 2006-04-03 2011-01-18 Hoffmann-La Roche Inc. Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
EP2007756B1 (fr) 2006-04-07 2015-08-26 Vertex Pharmaceuticals Incorporated Modulateurs des transporteurs de cassettes de liaison de l'atp
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
JP5497633B2 (ja) 2007-05-09 2014-05-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒのモジュレーター
PL2639223T3 (pl) 2007-12-07 2017-09-29 Vertex Pharmaceuticals Incorporated Sposób wytwarzania kwasów cykloalkilokarboksyamido-pirydyno-benzoesowych
SI2225230T1 (sl) 2007-12-07 2017-03-31 Vertex Pharmaceuticals Incorporated Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
WO2009105498A1 (fr) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines utilisées comme inhibiteurs de fak
CA2931134C (fr) 2008-02-28 2019-07-30 Vertex Pharmaceuticals Incorporated Derives heteroaryles convenant comme modulateurs du cftr
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
US8796269B2 (en) * 2009-08-27 2014-08-05 Nerre Therapeutics Limited Crystalline 2-(3,5-Bis(trifluoromethyl)phenyl)-N-(4-(4-fluoro-2-methylphenyl)-6-((7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)pyridin-3-yl)-N,2-dimethyl-propanamide of the formula (I), their use in therapy, and process for the preparation of the same
GEP20156226B (en) 2009-11-18 2015-01-26 Helsinn Healthcare Sa Ch Compositions for treating centrally mediated nausea and vomiting
EP2722045B1 (fr) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions pour traiter les nausées et vomissements à médiation centrale
TW201143768A (en) * 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN102933206A (zh) 2010-04-07 2013-02-13 弗特克斯药品有限公司 3-(6-(1-(2，2-二氟苯并[d][1，3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
MX342288B (es) 2010-04-22 2016-09-23 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2560488B1 (fr) * 2010-04-23 2015-10-28 Cytokinetics, Inc. Aminopyridines et aminotriazines, leurs compositions et leurs procédés d'utilisation
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
US20140155419A1 (en) * 2011-07-29 2014-06-05 Erkan Baloglu Compounds and methods
US20140256740A1 (en) * 2011-07-29 2014-09-11 Tempero Pharmaceuticals, Inc. Compounds and methods
US9358228B2 (en) 2011-10-18 2016-06-07 Helsinn Healthcare Sa Therapeutic combinations of netupitant and palonosetron
IN2014KN00885A (fr) 2011-11-08 2015-10-02 Vertex Pharma
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9012496B2 (en) 2012-07-16 2015-04-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
EP3067349B1 (fr) * 2013-11-08 2018-02-28 Kissei Pharmaceutical Co., Ltd. Dérivé de carboxyméthylpipéridine
RU2016122882A (ru) 2013-11-12 2017-12-19 Вертекс Фармасьютикалз Инкорпорейтед Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
ES2957761T3 (es) 2014-04-15 2024-01-25 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
EP3140007A1 (fr) * 2014-05-05 2017-03-15 Apicore US LLC Procédés de fabrication de nétupitant et d'intermédiaires de celui-ci
TWI649307B (zh) * 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
TW201613888A (en) 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
RU2691136C2 (ru) 2014-11-18 2019-06-11 Вертекс Фармасьютикалз Инкорпорейтед Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
MX2017011279A (es) 2015-03-04 2018-01-25 Vanda Pharmaceuticals Inc Metodo de tratamiento con tradipitant.
CN105061303A (zh) * 2015-08-03 2015-11-18 成都欣捷高新技术开发有限公司 一种制备奈妥吡坦关键中间体n-甲基-4-(2-甲基苯基)-6-(4-甲基-1-哌嗪基)-3-吡啶胺的新方法
WO2017044693A1 (fr) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Combinaison muscarinique et son utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central
EP3388423B1 (fr) 2015-12-07 2020-05-27 Kissei Pharmaceutical Co., Ltd. Antagoniste du récepteur nk1
TW202246215A (zh) * 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
CN106892864A (zh) * 2015-12-21 2017-06-27 上海科胜药物研发有限公司 一种奈妥皮坦游离碱的晶型a及其制备方法
CN115531553A (zh) 2015-12-22 2022-12-30 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂
KR20200002899A (ko) 2017-04-10 2020-01-08 체이스 테라퓨틱스 코포레이션 시누클레인병변을 치료하기 위한 nk1-길항제 배합물 및 방법
JP7158425B2 (ja) 2017-06-30 2022-10-21 チェイス セラピューティクス コーポレイション Ｎｋ－１アンタゴニスト組成物およびうつ病の処置における使用法
CN109384712B (zh) * 2017-08-14 2021-05-07 北京宽厚医药科技有限公司 靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用
EP3672964A4 (fr) 2017-08-21 2021-05-26 Leiutis Pharmaceuticals Pvt. Ltd. Nouvelles formulations à triple combinaison pour une thérapie antiémétique
CN111918701A (zh) * 2018-09-28 2020-11-10 万达制药公司 曲地匹坦在晕动病中的用途
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
JP2022514782A (ja) * 2018-12-24 2022-02-15 ユーストラリス ファーマシューティカルズ リミテッド （トレーディング アズ プレススラ ニューロ） 化合物の製造、その新しい塩形態および治療的使用
CN112174881B (zh) * 2019-07-04 2022-06-21 上海森辉医药有限公司 一种奈妥匹坦的衍生物及其制备方法
BR112022018876A2 (pt) 2020-04-03 2022-11-22 Nerre Therapeutics Ltd Antagonista de receptor de nk-1 para tratar uma doença selecionada a partir de sepse, choque séptico, síndrome de desconforto respiratório agudo (ards) ou síndrome de disfunção múltipla dos órgãos
WO2021245512A1 (fr) 2020-06-02 2021-12-09 Nerre Therapeutics Limited Antagonistes du récepteur de la neurokinine (nk)-1 destinés à être utilisés dans le traitement d'états de fibrose pulmonaire favorisés par une lésion mécanique des poumons

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1557420A (en) 1977-03-10 1979-12-12 Soc D Etudes Prod Chimique Preparation of isobutyramide derivatives
KR810001320B1 (ko) 1977-03-17 1981-10-14 삐에르 위브 신규한 이소부티라미드류의 제조방법
KR810001697B1 (ko) 1978-02-06 1981-10-27 삐에르 위브 이소부티라미드 유도체의 신규한 제조방법
EP0089765A3 (fr) 1982-03-17 1984-05-23 Smith Kline & French Laboratories Limited Dérivés de pyridine
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
GB8607312D0 (en) 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
GB8607313D0 (en) 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
CA1339423C (fr) 1988-09-14 1997-09-02 Yuji Ono Pyridines et leur emploi en pharmacie
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
US4973597A (en) 1989-06-30 1990-11-27 Eli Lilly And Company Anticonvulsant agents
HU207047B (en) 1989-11-07 1993-03-01 Richter Gedeon Vegyeszet Process for producing new pyridine derivatives and pharmaceutical copositions comprising same
US5364943A (en) 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
GB9021056D0 (en) 1990-09-27 1990-11-07 Pfizer Ltd Antiarrhythmic agents
GB9214120D0 (en) 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
AU4718093A (en) 1992-07-31 1994-03-03 Merck Sharp & Dohme Limited Substituted amines as tachykinin receptor antagonists
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
GB9305672D0 (en) 1993-03-19 1993-05-05 Wyeth John & Brother Ltd Amide derivatives
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
EP1462450B1 (fr) * 1993-12-29 2007-06-13 MERCK SHARP & DOHME LTD. Dérivés de morpholine substitués et leur application en tant qu'agents thérapeutiques
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
DE69523154T2 (de) 1994-06-06 2002-06-06 Warner Lambert Co Tachykinin (nk1) rezeptor antagonisten
US6294537B1 (en) 1995-03-17 2001-09-25 Sanofi-Synthelabo Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
ATE242243T1 (de) * 1995-03-24 2003-06-15 Takeda Chemical Industries Ltd Zyklische verbindungen, ihre herstellung und ihre verwendung als tachykininrezeptorantagonisten
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
DK0891332T3 (da) 1996-03-29 2004-07-05 Pfizer 6-phenylpyridyl-2-aminderivater
WO1998021185A1 (fr) 1996-11-08 1998-05-22 Sankyo Company, Limited Arylurees ou derives d'arylmethylcarbamyle
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
WO2000050398A2 (fr) * 1999-02-24 2000-08-31 F. Hoffmann-La Roche Ag Derives de pyridinyl et de phenyle
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
DE60006340T2 (de) * 1999-11-29 2004-09-09 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramid

Also Published As

Publication number Publication date
ITMI20000328A0 (it) 2000-02-23
UA71547C2 (uk) 2004-12-15
EA003673B1 (ru) 2003-08-28
US6479483B2 (en) 2002-11-12
CZ2000609A3 (cs) 2001-01-17
JP2000247957A (ja) 2000-09-12
HK1031223A1 (en) 2001-06-08
PA8491101A1 (es) 2001-04-30
EP1394150A1 (fr) 2004-03-03
DE60014216D1 (de) 2004-11-04
ES2171109B2 (es) 2003-09-16
MEP5709A (en) 2011-12-20
DK1035115T3 (da) 2005-01-24
TNSN00032A1 (fr) 2005-11-10
GEP20022676B (en) 2002-04-25
RS20080562A (en) 2009-09-08
SE1035115T5 (sv) 2015-08-04
US20020091265A1 (en) 2002-07-11
TR200000520A3 (tr) 2001-06-21
RS50194B (sr) 2009-05-06
AR062949A2 (es) 2008-12-17
IS2116B (is) 2006-06-15
HU227629B1 (en) 2011-10-28
YU9500A (sh) 2002-11-15
CA2299139C (fr) 2011-03-29
CA2299139A1 (fr) 2000-08-24
BR0000908A (pt) 2000-09-12
BRPI0000908B8 (pt) 2021-05-25
ATE277905T1 (de) 2004-10-15
ATE496032T1 (de) 2011-02-15
BG104187A (en) 2000-11-30
IS5381A (is) 2000-08-25
MA26722A1 (fr) 2004-12-20
CY2015041I1 (el) 2016-06-22
NZ502948A (en) 2001-09-28
MY123648A (en) 2006-05-31
HRP20000097B1 (en) 2008-12-31
ES2226622T3 (es) 2005-04-01
GB0003908D0 (en) 2000-04-05
GT200000017A (es) 2001-08-15
SK287912B6 (sk) 2012-03-02
NL300758I2 (fr) 2015-12-22
NO20000885L (no) 2000-08-25
ZA200000894B (en) 2000-08-24
TWI288746B (en) 2007-10-21
EP1394150B1 (fr) 2011-01-19
JO2294B1 (en) 2005-09-12
CY2015042I1 (el) 2016-06-22
HRP20080306A2 (en) 2008-11-30
GB2347422A (en) 2000-09-06
DE60014216T2 (de) 2006-03-02
BR0000908B1 (pt) 2013-09-24
NL300758I1 (fr) 2015-12-22
NO20000885D0 (no) 2000-02-23
IT1320763B1 (it) 2003-12-10
ES2359235T3 (es) 2011-05-19
OA11680A (fr) 2005-01-12
EP1035115B1 (fr) 2004-09-29
PL217311B1 (pl) 2014-07-31
TR200000520A2 (tr) 2001-06-21
HU0000748D0 (en) 2000-04-28
KR20000062599A (ko) 2000-10-25
LTPA2015036I1 (lt) 2015-11-25
RS53869B1 (en) 2015-08-31
DE60045564D1 (de) 2011-03-03
PE20001467A1 (es) 2000-12-20
EG23817A (en) 2007-09-19
AU767048B2 (en) 2003-10-30
SI1035115T1 (en) 2005-02-28
FR2790473A1 (fr) 2000-09-08
HRP20080306B1 (hr) 2015-01-30
DE10008042A1 (de) 2000-08-31
IL134654A (en) 2011-03-31
SK287911B6 (sk) 2012-03-02
CY1111317T1 (el) 2015-08-05
ME00593B (me) 2015-08-31
IL134654A0 (en) 2001-04-30
ITMI20000328A1 (it) 2001-08-23
ES2171109A1 (es) 2002-08-16
SE1035115T3 (sv) 2005-01-18
EA200000155A3 (ru) 2000-12-25
JP3399900B2 (ja) 2003-04-21
PT1035115E (pt) 2005-01-31
EA200000155A2 (ru) 2000-08-28
EP1035115A1 (fr) 2000-09-13
PT1394150E (pt) 2011-02-17
DK1394150T3 (da) 2011-03-21
CY2015041I2 (el) 2016-06-22
CN1270959A (zh) 2000-10-25
HUP0000748A3 (en) 2003-12-29
HUP0000748A2 (en) 2001-03-28
PL338598A1 (en) 2000-08-28
FR15C0049I2 (fr) 2016-02-12
LU92745I2 (fr) 2015-08-17
KR100384904B1 (ko) 2003-05-22
BG64554B1 (bg) 2005-07-29
HRP20000097A2 (en) 2001-10-31
SV2002000024A (es) 2002-01-23
NO315554B1 (no) 2003-09-22
AU1946800A (en) 2000-08-31
CN1142144C (zh) 2004-03-17
AR029614A1 (es) 2003-07-10
FR15C0049I1 (fr) 2015-08-28
SG91856A1 (en) 2002-10-15
BE2015C057I2 (fr) 2019-03-06
CZ300596B6 (cs) 2009-06-24
SK2352000A3 (en) 2000-09-12
UY32314A (es) 2010-02-26
US6297375B1 (en) 2001-10-02
LTC1035115I2 (lt) 2017-04-10
MY147451A (en) 2012-12-14

Similar Documents

Publication Publication Date Title
FR2790473B1 (fr) Nouveaux composes et medicaments les contenant
FR2783246B1 (fr) Derives d'azetidine, leur preparation et les medicaments les contenant
FR2789388B1 (fr) Composes stabilisants, composition les contenant et leur utilisation
DE69632354D1 (de) Behälter aus laminiertem, leicht schälbarem Material
DZ2086A1 (fr) Benzylaminopipéridines substituées et compositionspharmaceutiques les contenant.
PT1221918E (pt) Administracao de drogas sub-tenon
MA26549A1 (fr) Medicaments
MA26714A1 (fr) Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant
FR2805818B1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
EE200000484A (et) Täiustused ravimi väljastusseadmetele
DE69634053D1 (de) Oral anzuwendende Arzneizusammensetzung enthaltend 2-Methyl-thienobenzodiazepin
DE69938299D1 (de) Lokale abgabe von arzneimitteln
DE69940904D1 (de) Pharmazeutische zusammensetzung enthaltend epothilone
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
DZ2461A1 (fr) Dérivés d'arylkylamines nouveaux et composition pharmaceutiques les contenant.
DZ1916A1 (fr) Composés nouveaux et compostions pharmaceutiques les contenant.
LV12624A (lv) Thienylazolylalcoxyethanamines their preparation and their application as medicaments
DE69815169D1 (de) Aus Kunststoff hergestellter Reissverschluss
ATE332132T1 (de) Verbesserte arzneizubereitungen enthaltend ritonavir
FR2751969B1 (fr) Composes activateurs du canal cftr, et compositions pharmaceutiques les contenant
ID27150A (id) Sediaan levotiroksin bahan farmasi
ATE212225T1 (de) Injizierbare arzneizubereitung bestehend aus paracetamol
FR2796380B3 (fr) Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
FR2776659B1 (fr) Nouveaux composes heteroethynylenes et compositions pharmaceutiques et cosmetiques les contenant
FR2807043B1 (fr) Composition pharmaceutique contenant des oligosaccharides, les nouveaux oligosaccharides et leur preparation

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20081031